Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Patrick Oeckl; Steffen Halbgebauer; Sarah Anderl-Straub; Petra Steinacker; Andre M. Hussa; Hermann Neugebauer; Christine A.F. Von Arnim; Janine Diehl-Schmid; Timo Grimmer; Johannes Kornhuber; Piotr Lewczuk; Adrian Danek; Lobar Degeneration; Albert C. Ludolph; Markus Otto

doi:10.3233/JAD-180325

Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Patrick Oeckl, Steffen Halbgebauer, Sarah Anderl-Straub, Petra Steinacker, Andre M. Hussa, Hermann Neugebauer, Christine A.F. Von Arnim, Janine Diehl-Schmid, Timo Grimmer, Johannes Kornhuber, Piotr Lewczuk, Adrian Danek, Lobar Degeneration, Albert C. Ludolph, Markus Otto

Research output: Contribution to journal › Article › peer-review

191 Scopus citations

Abstract

Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

Original language	English
Pages (from-to)	481-488
Number of pages	8
Journal	Journal of Alzheimer's Disease
Volume	67
Issue number	2
DOIs	https://doi.org/10.3233/JAD-180325
State	Published - 2019
Externally published	Yes

Keywords

Alzheimer's disease
GFAP
Lewy body dementia
Parkinson's disease
astrocyte
biomarker
cerebrospinal fluid
differential diagnosis
frontotemporal dementia
serum

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3233/JAD-180325

Cite this

Oeckl, P., Halbgebauer, S., Anderl-Straub, S., Steinacker, P., Hussa, A. M., Neugebauer, H., Von Arnim, C. A. F., Diehl-Schmid, J., Grimmer, T., Kornhuber, J., Lewczuk, P., Danek, A., Degeneration, L., Ludolph, A. C., & Otto, M. (2019). Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment. Journal of Alzheimer's Disease, 67(2), 481-488. https://doi.org/10.3233/JAD-180325

@article{9e44a9de866042d6991e43e943e40c01,

title = "Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment",

abstract = "Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.",

keywords = "Alzheimer's disease, GFAP, Lewy body dementia, Parkinson's disease, astrocyte, biomarker, cerebrospinal fluid, differential diagnosis, frontotemporal dementia, serum",

author = "Patrick Oeckl and Steffen Halbgebauer and Sarah Anderl-Straub and Petra Steinacker and Hussa, {Andre M.} and Hermann Neugebauer and {Von Arnim}, {Christine A.F.} and Janine Diehl-Schmid and Timo Grimmer and Johannes Kornhuber and Piotr Lewczuk and Adrian Danek and Lobar Degeneration and Ludolph, {Albert C.} and Markus Otto",

year = "2019",

doi = "10.3233/JAD-180325",

language = "English",

volume = "67",

pages = "481--488",

journal = "Journal of Alzheimer's Disease",

issn = "1387-2877",

publisher = "IOS Press BV",

number = "2",

}

Oeckl, P, Halbgebauer, S, Anderl-Straub, S, Steinacker, P, Hussa, AM, Neugebauer, H, Von Arnim, CAF, Diehl-Schmid, J , Grimmer, T, Kornhuber, J, Lewczuk, P, Danek, A, Degeneration, L, Ludolph, AC & Otto, M 2019, 'Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment', Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 481-488. https://doi.org/10.3233/JAD-180325

TY - JOUR

T1 - Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

AU - Oeckl, Patrick

AU - Halbgebauer, Steffen

AU - Anderl-Straub, Sarah

AU - Steinacker, Petra

AU - Hussa, Andre M.

AU - Neugebauer, Hermann

AU - Von Arnim, Christine A.F.

AU - Diehl-Schmid, Janine

AU - Grimmer, Timo

AU - Kornhuber, Johannes

AU - Lewczuk, Piotr

AU - Danek, Adrian

AU - Degeneration, Lobar

AU - Ludolph, Albert C.

AU - Otto, Markus

PY - 2019

Y1 - 2019

N2 - Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

AB - Reliable blood biomarkers for Alzheimer's disease (AD) are missing. We measured astroglial GFAP in patients with AD (n = 28), frontotemporal dementia (bvFTD, n = 35), Parkinson's disease (n = 11), Lewy body dementias (n = 19), and controls (n = 34). Serum GFAP was increased in AD (p < 0.001) and DLB/PDD (p < 0.01), and cerebrospinal fluid GFAP was increased in all neurodegenerative diseases (p < 0.001). Serum GFAP correlated with the Mini-Mental State Examination score (r =-0.42, p < 0.001) and might be a follow-up marker in clinical trials. Sensitivity and specificity of serum GFAP for AD versus bvFTD was 89% and 79% and might be the first blood biomarker in the differential diagnosis of AD and bvFTD.

KW - Alzheimer's disease

KW - GFAP

KW - Lewy body dementia

KW - Parkinson's disease

KW - astrocyte

KW - biomarker

KW - cerebrospinal fluid

KW - differential diagnosis

KW - frontotemporal dementia

KW - serum

UR - http://www.scopus.com/inward/record.url?scp=85060574339&partnerID=8YFLogxK

U2 - 10.3233/JAD-180325

DO - 10.3233/JAD-180325

M3 - Article

C2 - 30594925

AN - SCOPUS:85060574339

SN - 1387-2877

VL - 67

SP - 481

EP - 488

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

IS - 2

ER -

Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this